Safe reopening of university campuses is possible with COVID-19 vaccination

We construct an agent-based SEIR model to simulate COVID-19 spread at a 16000-student mostly non-residential urban university during the Fall 2021 Semester. We find that mRNA vaccine coverage at 100% combined with weekly screening testing of 25% of the campus population make it possible to safely re...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2022-07, Vol.17 (7), p.e0270106
Main Authors: Junge, Matthew, Li, Sheng, Samaranayake, Samitha, Zalesak, Matthew
Format: Article
Language:English
Subjects:
Biology and Life Sciences
College campuses
Colleges & universities
Combined vaccines
Computer and Information Sciences
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines
Evaluation
Health risks
Humans
Infections
Management
Medicine and Health Sciences
mRNA
mRNA Vaccines
Physical Sciences
Research and Analysis Methods
School management and organization
Students
Universities
Vaccination
Vaccine efficacy
Vaccines
Vaccines, Synthetic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We construct an agent-based SEIR model to simulate COVID-19 spread at a 16000-student mostly non-residential urban university during the Fall 2021 Semester. We find that mRNA vaccine coverage at 100% combined with weekly screening testing of 25% of the campus population make it possible to safely reopen to in-person instruction. Our simulations exhibit a right-skew for total infections over the semester that becomes more pronounced with less vaccine coverage, less vaccine effectiveness and no additional preventative measures. This suggests that high levels of infection are not exceedingly rare with campus social connections the main transmission route. Finally, we find that if vaccine coverage is 100% and vaccine effectiveness is above 80%, then a safe reopening is possible even without facemask use. This models possible future scenarios with high coverage of additional "booster" doses of COVID-19 vaccines.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0270106